Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. As of 2025, it had two ongoing Phase I/II clinical trials evaluating potential therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena is bringing patients into focus with ocular gene therapy, overcoming the hurdles presented by inherited retinal disease on a patient-specific basis.

Additional Details

Company Size:

10-49 Employees